How AI agents will change cancer research and oncology
- PMID: 39690222
- DOI: 10.1038/s43018-024-00861-7
How AI agents will change cancer research and oncology
Conflict of interest statement
Competing interests: D.F. has received a research grant from OpenAI and holds shares and is an employee at Synagen GmbH. Y.L., J.E.R. and A.R. are employees of Genentech, a member of the Roche Group. J.E.R. and A.R. have equity in Roche. A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and until 31 July 2020 was on the scientific advisory board of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. J.N.K. declares consulting services for Bioptimus, Owkin, DoMore Diagnostics, Panakeia, AstraZeneca, Scailyte, Mindpeak and MultiplexDx; hold shares in StratifAI GmbH and Synagen GmbH; has received a research grant from GSK; and has received honoraria from AstraZeneca, Bayer, Eisai, Janssen, MSD, BMS, Roche, Pfizer and Fresenius.
References
LinkOut - more resources
Full Text Sources